Please login to the form below

Not currently logged in

Novaliq GmbH appoints Friedrich von Bolen as chairman

And Gerald Cagle joins as a member of the supervisory board

Heidelberg-based Novaliq has named Friedrich von Bolen as chairman of its supervisory board, which Gerald Cagle also joins as a board member.

Dr von Bolen, co-founder of dievini Hopp Bio Tech and Lion Bioscience AG, brings to the role 20 years of entrepreneurial experience and has been active in the life sciences industry since 1997.

He currently serves on several of the dievini portfolio's supervisory boards and has been chairman of Lion Bioscience's board since 2004.

Novaliq's chief executive officer and managing director Bernard Günther said: “We are pleased to have Friedrich join Novaliq as the chairman of our supervisory board.

His 20 years of entrepreneurial experience is of great importance for the further prosperity of the company and especially in building a successful specialty pharma company focusing on ophthalmology.”

Prior to his appointment as a board member of Novaliq, Dr Cagle was senior vice president of Alcon R&D and chief scientific officer from 1996 to mid-2008 having worked as a member of Alcon's research and development team for over thirty years.

He has since worked on the management of Alzheimer's disease and serves on the boards of Aerie Pharmaceuticals, Clearside Biomedical, AB2 and GrayBug.

Dr von Bohlen, new chairman of the supervisory board, said: “Gerald's broad business and R&D background in this industry is an important contribution and will be crucial for Novaliq with regard to the evaluation and development of highly effective ocular therapeutics.” 

7th January 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?